BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 10, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Abilify aripiprazole regulatory update

The U.K.'s NICE issued draft guidance recommending the use of Abilify aripiprazole from Otsuka and Bristol-Myers to treat moderate to severe manic episodes in adolescents ages >=13 years with bipolar I disorder for up to 12 weeks - its approved indication. The committee concluded that Abilify was as effective as other...

Read the full 231 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >